Cargando…

CEP72‐ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next‐generation sequencing

ROS1 rearrangement is a validated therapeutic driver gene in non‐small cell lung cancer (NSCLC) and represents a small subset (1–2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi‐targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, You‐cai, Zhou, Yue‐fen, Wang, Wen‐xian, Xu, Chun‐wei, Zhuang, Wu, Du, Kai‐qi, Chen, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928353/ https://www.ncbi.nlm.nih.gov/pubmed/29517860 http://dx.doi.org/10.1111/1759-7714.12617

Ejemplares similares

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
por: Xu, Shuguang, et al.
Publicado: (2019)

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma
por: Zhu, You-Cai, et al.
Publicado: (2019)

Detection of ROS1 gene fusions using next-generation sequencing for patients with malignancy in China
por: Li, Ning, et al.
Publicado: (2022)

Dual drive coexistence of EML4‐ALK and TPM3‐ROS1 fusion in advanced lung adenocarcinoma
por: Zhu, You‐cai, et al.
Publicado: (2017)

Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing
por: Nagasaka, Misako, et al.
Publicado: (2023)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
por: Huang, Richard S.P., et al.
Publicado: (2020)

Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
por: Lin, Jessica J., et al.
Publicado: (2020)

Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib
por: Xu, Long, et al.
Publicado: (2021)

Discovery and functional characterization of the oncogenicity and targetability of a novel NOTCH1–ROS1 gene fusion in pediatric angiosarcoma
por: Jain, Payal, et al.
Publicado: (2022)

Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib
por: Kian, Waleed, et al.
Publicado: (2023)

Nasopharyngeal papillary adenocarcinoma harboring a fusion of ROS1 with GOPC: A case report
por: Wang, Jinjing, et al.
Publicado: (2021)

MAP17, a ROS-dependent oncogene
por: Carnero, Amancio
Publicado: (2012)

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma
por: Lan, Shaowei, et al.
Publicado: (2020)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Loss of Cep72 affects the morphology of spermatozoa in mice
por: Chen, Zhen, et al.
Publicado: (2022)

Next Generation Sequencing Reveals a Synchronous Trilateral Lung Adenocarcinoma Case with Distinct Driver Alterations of EGFR 19 Deletion or EGFR 20 Insertion or EZR-ROS1 Fusion
por: Zhang, Xuhui, et al.
Publicado: (2020)

Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
por: Zhao, Zheng, et al.
Publicado: (2017)

Concomitant and decoupled effects of cigarette smoke and SCAL1 upregulation on oncogenic phenotypes and ROS detoxification in lung adenocarcinoma cells
por: Cruz, Carmela Rieline V., et al.
Publicado: (2021)

The centriolar satellite proteins Cep72 and Cep290 interact and are required for recruitment of BBS proteins to the cilium
por: Stowe, Timothy R., et al.
Publicado: (2012)

OPRM1-ROS1 Fusion Detected by Next-Generation Sequencing with Circulating DNA in a Patient with EGFR Mutated Advanced NSCLC: A Case Report
por: Zhang, Sicai, et al.
Publicado: (2022)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
por: Iyer, Sudarshan R, et al.
Publicado: (2023)

Multiple cerebral infarctions in ROS1‐rearranged lung adenocarcinoma
por: Ikushima, Hiroaki, et al.
Publicado: (2021)

CCHCR1-astrin interaction promotes centriole duplication through recruitment of CEP72
por: Ying, Zhenguang, et al.
Publicado: (2022)

GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types
por: Sievers, Philipp, et al.
Publicado: (2021)

HGG-13. ONCOGENIC STAT3 AND SHP2 ACTIVATION IN ROS1-FUSION DRIVEN INFANT-TYPE HEMISPHERIC GLIOMAS
por: Postlmayr, Andreas, et al.
Publicado: (2023)

GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop
por: Giacco, Ferdinando, et al.
Publicado: (2015)

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma
por: Grenier, Karl, et al.
Publicado: (2023)

A case of CD74‐ROS1‐positive lung adenocarcinoma diagnosed by next‐generation sequencing achieved long‐term survival with pemetrexed regimens
por: Tanaka, Satoshi, et al.
Publicado: (2023)

Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach
por: Yoon, Hyun Jung, et al.
Publicado: (2015)

Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report
por: Yang, Tao, et al.
Publicado: (2018)

Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients
por: Novaes, Lázaro Antonio Campanha, et al.
Publicado: (2021)

Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma
por: Ribeiro, Maurício Fernando Silva Almeida, et al.
Publicado: (2022)

Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age
por: Ke, Li, et al.
Publicado: (2018)

Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
por: Chen, Hua-fei, et al.
Publicado: (2018)

Response to Entrectinib in Differentiated Thyroid Cancer With a ROS1 Fusion
por: Liu, Stephen V., et al.
Publicado: (2017)

Clinical, Morphologic and Genomic Findings in ROS1 Fusion Spitz Neoplasms.
por: Gerami, Pedram, et al.
Publicado: (2020)

The ortholog of the human proto-oncogene ROS1 is required for epithelial development in C. elegans
por: Jones, Martin R, et al.
Publicado: (2013)

EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis
por: Shih, C-H, et al.
Publicado: (2017)

A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib
por: Hashiguchi, Mizuha Haraguchi, et al.
Publicado: (2021)

RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer
por: Isidori, Federica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fjun3ut358uub4pah4groibnb8